ADHD drug 'harmonizes' with body's dopamine system, gives hint to effect on children, adults

June 05, 2006

SAN DIEGO, Calif.--The brain's dopamine system, which has long been associated with reward learning and reward-related behavior, works differently in treated and untreated attention deficit hyperactivity disorder (ADHD) individuals, according to a study presented by German researchers at SNM's 53rd Annual Meeting June 3-7 in San Diego.

"The significant difference we found between treated and untreated ADHD patients provides an important hint on the effect of the most commonly prescribed drug for this disease, which has long baffled and frustrated parents and physicians," noted Felix M Mottaghy, research fellow at University Ulm in Germany. Until this study, there has been no direct evidence pointing to the beneficial effect of methylphenidate (drugs like Ritalin) on the body's dopamine system, added the co-author of "Midbrain, Striatal and Amygdalar Dopaminergic Dysfunction in Attention Deficit Hyperactivity Disorder (ADHD)." For years, researchers have speculated that methylphenidate calms people with ADHD by amplifying the release of the neurotransmitter dopamine, improving attention and focus in those who have weak dopamine signals. "This is a very preliminary basic science study, initiated by Andrea G. Ludolph from the child and youth psychiatry department of the University Ulm; however, future studies of the dopamine system could aid differential diagnosis in hyperactive children," said Mottaghy.

The principal characteristics of ADHD are inattention, hyperactivity and impulsivity, and this condition can become apparent early in a child's life--sometimes as soon as preschool. Estimates indicate that there are as many as 2 million ADHD children (or 1 in every classroom of about 25 students) in the United States. With ADHD, there is an imbalance of several neurotransmitter systems, said Mottaghy. "The most affected seemed to be the dopaminergic system. Until now most studies focused on the so-called postsynaptic or receiving part of this system," he explained. "Our study shows that the beneficial effect of methylphenidate is received via 'normalization' of the dopamine system," he added. "We demonstrated that the brain's dopamine system--including midbrain, the striatum and the amygdala--is differentially modulated in treated and untreated ADHD patients with respect to healthy normal controls," noted Mottaghy. "Methylphenidate leads to a harmonization of the presynaptic dopaminergic neurons that could explain in part the beneficial effects of this central nervous system stimulant," he indicated.

The researchers used positron emission tomography (PET), a noninvasive brain scan, with 18F-DOPA, an imaging drug that is a precursor of dopamine. The University Ulm researchers also used statistic parametric mapping to obtain the statistical comparison of normalized and reoriented brain images, said Mottaghy. "It gives an impression of the distribution of differences within the brain comparing groups of patients or different conditions within one subject," he explained. Additional studies with more subjects need to be undertaken, said Mottaghy, including direct comparison of presynaptic and postsynaptic alterations in an age-matched patients group.
Abstract: F.M. Mottaghy, C. Glaser, B. Neumaier, S. Thees, A.K. Buck, B.J. Krause and S.N. Reske, all nuclear medicine, University Ulm, Ulm, Germany, and A.G. Ludolph, K. Schmeck and J.M. Fegert, child and youth psychiatry, University Ulm, Ulm, Germany, "Midbrain, Striatal and Amygdalar Dopaminergic Dysfunction in Attention Deficit Hyperactivity Disorder (ADHD)," SNM's 53rd Annual Meeting, June 3-7, 2006, Scientific Poster 1240.

About SNM

SNM is holding its 53rd Annual Meeting June 3-7 at the San Diego Convention Center. Research topics for the 2006 meeting include molecular imaging in clinical practice in the fight against cancer; the role of diagnostic imaging in the management of metastatic bone disease, metabolic imaging for heart disease, neuroendocrine and brain imaging, new agents for imaging infection and inflammation, and an examination of dementia, neurodegeneration, movement disorders and thyroid cancer.

SNM is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of molecular and nuclear imaging to diagnose, manage and treat diseases in women, men and children. Founded more than 50 years ago, SNM continues to provide essential resources for health care practitioners and patients; publish the most prominent peer-reviewed journal in the field; host the premier annual meeting for medical imaging; sponsor research grants, fellowships and awards; and train physicians, technologists, scientists, physicists, chemists and radiopharmacists in state-of-the-art imaging procedures and advances. SNM members have introduced--and continue to explore--biological and technological innovations in medicine that noninvasively investigate the molecular basis of diseases, benefiting countless generations of patients. SNM is based in Reston, Va.; additional information can be found online at

Society of Nuclear Medicine

Related ADHD Articles from Brightsurf:

Autism and ADHD share genes
Researchers from the national psychiatric project iPSYCH have found that autism and ADHD share changes in the same genes.

ADHD across racial/ethnic groups
This study of patients from diverse racial/ethnic backgrounds who received care at the Kaiser Permanente Northern California health system looked at how common attention-deficit/hyperactivity disorder (ADHD) diagnoses were over a 10-year period across seven racial/ethnic groups.

Cycles of reward: New insight into ADHD treatment
Researchers at the Okinawa Institute of Science and Technology Graduate University (OIST) in collaboration with scientists at the University of Otago and the University of Auckland in New Zealand, investigated the actions of the drug in rats.

Young mums more likely to have kids with ADHD
Young mothers have a greater chance of having a child with attention deficit hyperactivity disorder (ADHD) according to new research from the University of South Australia.

ADHD medication: How much is too much for a hyperactive child?
When children with ADHD don't respond well to Methylphenidate (MPH, also known as Ritalin) doctors often increase the dose.

Antipsychotic use in youths with ADHD is low, but still cause for concern
A new study eased fears about the proportion of youths with ADHD taking antipsychotic drugs, but still found that many prescriptions may be inappropriate.

How stimulant treatment prevents serious outcomes of ADHD
Analysis quantifies the extent which stimulant treatment reduces serious outcomes in children and young adults with ADHD.

Did Leonardo da Vinci have ADHD?
Leonardo da Vinci produced some of the world's most iconic art, but historical accounts show that he struggled to complete his works.

More sleep may help teens with ADHD focus and organize
Teenagers with attention deficit hyperactivity disorder (ADHD) may benefit from more sleep to help them focus, plan and control their emotions.

Researchers have found the first risk genes for ADHD
A major international collaboration headed by researchers from the Danish iPSYCH project, the Broad Institute of Harvard and MIT, Massachusetts General Hospital, SUNY Upstate Medical University, and the Psychiatric Genomics Consortium has for the first time identified genetic variants which increase the risk of ADHD.

Read More: ADHD News and ADHD Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to